We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Fluidigm

Fluidigm Corporation focuses on the most pressing needs in translational and clinical research, including cancer, imm... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Biomarkers Associated with Major Bleeding in Patients with Atrial Fibrillation

By LabMedica International staff writers
Posted on 16 Nov 2021
Print article
Image: The BioMark HD real-time Polymerase Chain reaction (PCR) platform (Photo courtesy of Fluidigm)
Image: The BioMark HD real-time Polymerase Chain reaction (PCR) platform (Photo courtesy of Fluidigm)
Atrial fibrillation (AF) is associated with a five-fold increased risk of thromboembolisms, mainly stroke, independently of other risk factors. Accurate assessment to balance the risk of stroke and systemic embolic events (S/SEE), against the risk of major bleeding is therefore an important therapeutic goal in the clinical management of these patients.

Age, prior hemorrhage, severe renal disease, and anemia (hemoglobin) have been independently associated with an increased risk of major bleeding in patients with AF. The use of different combinations of these mainly clinical variables has resulted in at least five validated risk scores for better prediction of bleeding events in patients with AF.

Medical Scientists at Uppsala University (Uppsala, Sweden) explored associations between a wide range of biomarkers and bleeding risk in patients with AF on oral anticoagulants (OAC). Biomarkers were analyzed in a random sample of 4,200 patients, 204 cases with major bleedings. The replication cohort included 344 cases with major bleeding and 1,024 random controls.

The plasma concentrations of high-sensitivity cTnT-hs, NT-proBNP, and GDF-15 were determined by Roche immunoassays using a Cobas Analytics e601 (Roche Diagnostics, Rotkreuz, Switzerland). Interleukin 6 (IL-6) was analyzed using the high-sensitivity sandwich ELISA immunoassay (R&D Systems Inc, Minneapolis, MN, USA) and Cystatin C with the ARCHITECT system ci8200 (Abbott Laboratories, Abbott Park, IL, USA) using the particle-enhanced turbidimetric immunoassay (PETIA) from Gentian Diagnostics ASA (Moss, Norway).

The proteomic analyses were performed with the high-throughput Proximity Extension Assay (PEA) technique using the Target 96 Multiplex CVD II, CVD III, and Inflammation panels (Olink Proteomics, Uppsala, Sweden), which together simultaneously measured 276 selected proteins in plasma potentially related to CVD and inflammation. The PEA technology uses pairs of antibodies equipped with DNA reporter molecules When binding to their correct targets, antibody pairs give rise to new DNA amplicons each ID-barcoding their respective antigens. The amplicons are subsequently quantified using the Fluidigm BioMark HD real-time PCR platform (Fluidigm, South San Francisco, CA, USA).

The investigators reported that out of 268 proteins, nine biomarkers were independently associated with bleeding in both cohorts. In the replication cohort a significant linear hazard ratios per interquartile range were confirmed for these biomarkers: cytokine GDF-15, cTnT-hs, osteopontin (OPN), ephrin type-B receptor 4 (EphB4), TNF-R1, TNF-R2, soluble urokinase plasminogen activator receptor (suPAR), TRAIL-R2, and osteoprotegerin (OPG).

The authors concluded that in patients with AF on OAC, GDF-15, cTnT-hs, and seven novel biomarkers were independently associated with major bleedings and reflect pathophysiologic processes of inflammation, apoptosis, oxidative stress, vascular calcification, coagulation, and fibrinolysis. Investigations of the utility of these markers to refine risk stratification and guide the management of patients at high risk of bleeding are warranted. The study was published on the November 2021 issue of the Journal of Thrombosis and Haemostasis.

Related Links:
Uppsala University
Roche Diagnostics
R&D Systems
Abbott Laboratories
Gentian Diagnostics
Olink Proteomics
Fluidigm


New
Gold Supplier
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
New
STI Test
Rheonix STI TriPlex Assay
New
Silver Supplier
SARS-CoV-2, Influenza A/B Test
REALQUALITY ABFlu-Cov-2
New
Anti-HIV 1/2 ELISA Test
HIV 1/2 Antibody (3rd) Test Kit (ELISA)

Print article
IIR Middle East

Channels

Technology

view channel
Image: OneDraw Blood Collection Device significantly reduces obstacles for drawing blood (Photo courtesy of Drawbridge Health)

Near Pain-Free Blood Collection Technology Enables High-Quality Testing

Blood tests help doctors diagnose diseases and conditions such as cancer, diabetes, anemia, and coronary heart disease, as well as evaluate organ functionality. They can also be used to identify disease... Read more

Industry

view channel
Image: The global infectious disease IVD market is expected to hit USD 57 billion by 2030 (Photo courtesy of Pexels)

Global Infectious Disease IVD Market Dominated by Molecular Diagnostics Technology

The global infectious disease in vitro diagnostics (IVD) market stood at USD 113.7 billion in 2021 and is expected to grow at a CAGR of -7.41% from 2022 to 2030 to hit around USD 56.89 billion by 2030,... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.